Emerging trends of research on mRNA vaccines: A co-citation analysis

References

• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):1–17. doi:10.1038/nrd.2017.243.
   PubMed Web of Science ®Google Scholar
• Dolgin E. The tangled history of mRNA vaccines. Nature. 2021;597(7876):318–324. doi:10.1038/d41586-021-02483-w.
   PubMed Web of Science ®Google Scholar
• Sahin U, Kariko K, Tureci O. mRNA-Based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–780. doi:10.1038/nrd4278.
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–1468. doi:10.1126/science.1690918.
   PubMed Web of Science ®Google Scholar
• Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, Bloom FE. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science. 1992;255(5047):996–998. doi:10.1126/science.1546298.
   PubMed Web of Science ®Google Scholar
• Martinon F, Krishnan S, Lenzen G, Magné R, Gomard E, Guillet J-G, Lévy J-P, Meulien P. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol. 1993;23(7):1719–1722. doi:10.1002/eji.1830230749.
   PubMed Web of Science ®Google Scholar
• Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–1094. doi:10.1038/s41578-021-00358-0.
   PubMed Web of Science ®Google Scholar
• Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–1840. doi:10.1038/mt.2008.200.
   PubMed Web of Science ®Google Scholar
• Flanagan KL, MacIntyre CR, McIntyre PB, Nelson MR. SARS-CoV-2 vaccines: where are we now? J Allergy Clin Immunol Pract. 2021;9(10):3535–3543. doi:10.1016/j.jaip.2021.07.016.
   PubMed Web of Science ®Google Scholar
• Sharma K, Koirala A, Nicolopoulos K, Chiu C, Wood N, Britton PN. Vaccines for COVID-19: where do we stand in 2021? Paediatr Respir Rev. 2021;39:22–31. doi:10.1016/j.prrv.2021.07.001.
   PubMed Web of Science ®Google Scholar
• Synnestvedt MB, Chen C, Holmes JH. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc. 2005;724–728.
   PubMedGoogle Scholar
• Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci USA. 2004;101 Suppl 1:5303–5310. doi:10.1073/pnas.0307513100.
   PubMed Web of Science ®Google Scholar
• Chen CM. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Tec. 2006;57(3):359–377. doi:10.1002/asi.20317.
   Web of Science ®Google Scholar
• Price DJ. Networks of scientific papers. Science. 1965;149(3683):510–515. doi:10.1126/science.149.3683.510.
   PubMed Web of Science ®Google Scholar
• Chen C, Hu Z, Liu S, Tseng H. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther. 2012;12(5):593–608. doi:10.1517/14712598.2012.674507.
   PubMed Web of Science ®Google Scholar
• Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000;30:1–7.
   PubMed Web of Science ®Google Scholar
• Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, Rammensee H-G, Garbe C, Pascolo S. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother (1991). 2008;31(2):180–188. doi:10.1097/CJI.0b013e31815ce501.
   PubMed Web of Science ®Google Scholar
• Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee H-G, Garbe C. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother (1991). 2009;32(5):498–507. doi:10.1097/CJI.0b013e3181a00068.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci Ö, Sahin U. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010;70(22):9031–9040. doi:10.1158/0008-5472.CAN-10-0699.
   PubMed Web of Science ®Google Scholar
• Pollard C, Rejman J, De Haes W, Verrier B, Van Gulck E, Naessens T, De Smedt S, Bogaert P, Grooten J, Vanham G. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013;21(1):251–259. doi:10.1038/mt.2012.202.
   PubMed Web of Science ®Google Scholar
• De Haes W, Rejman J, Pollard C, Merlin C, Vekemans M, Florence E, De Smedt SC, Grooten J, Vanham G, De Koker S. Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells to stimulate HIV-specific immune responses. Nanomedicine (Lond). 2013;8(1):77–87. doi:10.2217/nnm.12.97.
   PubMed Web of Science ®Google Scholar
• Yang Z, Bruno DP, Martens CA, Porcella SF, Moss B. Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci USA. 2010;107(25):11513–11518. doi:10.1073/pnas.1006594107.
   PubMed Web of Science ®Google Scholar
• Bullard JH, Purdom E, Hansen KD, Dudoit S. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC Bioinform. 2010;11:94. doi:10.1186/1471-2105-11-94.
   PubMed Web of Science ®Google Scholar
• Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, Coch C, Janke M, Mihailovic A, Wardle G. Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity. 2009;31(1):25–34. doi:10.1016/j.immuni.2009.05.008.
   PubMed Web of Science ®Google Scholar
• Pichlmair A, Schulz O, Tan CP, Rehwinkel J, Kato H, Takeuchi O, Akira S, Way M, Schiavo G, Reis E Sousa C. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J Virol. 2009;83(20):10761–10769. doi:10.1128/JVI.00770-09.
   PubMed Web of Science ®Google Scholar
• Myskiw C, Arsenio J, Booy EP, Hammett C, Deschambault Y, Gibson SB, Cao J. RNA species generated in vaccinia virus infected cells activate cell type-specific MDA5 or RIG-I dependent interferon gene transcription and PKR dependent apoptosis. Virology. 2011;413(2):183–193. doi:10.1016/j.virol.2011.01.034.
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001;98(1):49–56. doi:10.1182/blood.V98.1.49.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–252. doi:10.1038/32588.
   PubMed Web of Science ®Google Scholar
• Allard SD, De Keersmaecker B, de Goede AL, Verschuren EJ, Koetsveld J, Reedijk ML, Wylock C, De Bel AV, Vandeloo J, Pistoor F. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin Immunol. 2012;142(3):252–268. doi:10.1016/j.clim.2011.10.010.
   PubMed Web of Science ®Google Scholar
• Coosemans A, Wolfl M, Berneman ZN, Van Tendeloo V, Vergote I, Amant F, Van Gool SW. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res. 2010;30:3709–3714.
   PubMed Web of Science ®Google Scholar
• Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345–351. doi:10.1016/j.jconrel.2015.08.007.
   PubMed Web of Science ®Google Scholar
• Laczko D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, Castaño D, Amanat F, Muramatsu H, Oguin TH, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020;53(4):724–732. doi:10.1016/j.immuni.2020.07.019.
   PubMed Web of Science ®Google Scholar
• Freyn AW, Ramos DSJ, Rosado VC, Bliss CM, Pine M, Mui BL, Tam YK, Madden TD, de Souza Ferreira LC, Weissman D. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Ther. 2020;28(7):1569–1584. doi:10.1016/j.ymthe.2020.04.018.
   PubMed Web of Science ®Google Scholar
• Willis E, Pardi N, Parkhouse K, Mui BL, Tam YK, Weissman D, Hensley SE. Nucleoside-Modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice. Sci Transl Med. 2020;12(525). doi:10.1126/scitranslmed.aav5701.
   PubMed Web of Science ®Google Scholar
• Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594–599. doi:10.1038/s41586-020-2814-7.
   PubMed Web of Science ®Google Scholar
• Ahammad I, Lira SS. Designing a novel mRNA vaccine against SARS-CoV-2: an immunoinformatics approach. Int J Biol Macromol. 2020;162:820–837. doi:10.1016/j.ijbiomac.2020.06.213.
   PubMed Web of Science ®Google Scholar
• Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA. 2012;109(36):14604–14609. doi:10.1073/pnas.1209367109.
   PubMed Web of Science ®Google Scholar
• Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A. Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect. 2013;2(1):e52. doi:10.1038/emi.2013.54.
   PubMedGoogle Scholar
• Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, Wicke L, Perkovic M, Beissert T, Haas H. Self-Amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. 2018;26(2):446–455. doi:10.1016/j.ymthe.2017.11.017.
   PubMed Web of Science ®Google Scholar
• Anderluzzi G, Lou G, Gallorini S, Brazzoli M, Johnson R, O’Hagan DT, Baudner BC, Perrie Y. Investigating the impact of delivery system design on the efficacy of self-amplifying RNA vaccines. Vaccines (Basel). 2020;8(2). doi:10.3390/vaccines8020212.
   PubMed Web of Science ®Google Scholar
• Blakney AK, Zhu Y, McKay PF, Bouton CR, Yeow J, Tang J, Hu K, Samnuan K, Grigsby CL, Shattock RJ. Big is beautiful: enhanced saRNA delivery and immunogenicity by a higher molecular weight, bioreducible, cationic polymer. Acs Nano. 2020;14(5):5711–5727. doi:10.1021/acsnano.0c00326.
   PubMed Web of Science ®Google Scholar
• Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, Giusti F, Ferlenghi I, Johnson RN, Roberts CW. Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: the impact of cationic lipid selection. J Control Release. 2020;325:370–379. doi:10.1016/j.jconrel.2020.06.027.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543(7644):248–251. doi:10.1038/nature21428.
   PubMed Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC. Modified mRNA vaccines protect against zika virus infection. Cell. 2017;168(6):1114–1125. doi:10.1016/j.cell.2017.02.017.
   PubMed Web of Science ®Google Scholar
• Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, Himansu S, Caine EA, Nunes BTD, Medeiros DBA. Vaccine mediated protection against zika virus-induced congenital disease. Cell. 2017;170(2):273–283. doi:10.1016/j.cell.2017.06.040.
   PubMed Web of Science ®Google Scholar
• Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Türeci O, Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009–4017. doi:10.1182/blood-2006-04-015024.
   PubMed Web of Science ®Google Scholar
• Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, Vergote I, Amant F, VAN Gool SW. Wilms’ tumor gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res. 2013;33:5495–5500.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–226. doi:10.1038/nature23003.
   PubMed Web of Science ®Google Scholar
• Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107–112. doi:10.1038/s41586-020-2537-9.
   PubMed Web of Science ®Google Scholar
• Salomon N, Vascotto F, Selmi A, Vormehr M, Quinkhardt J, Bukur T, Schrörs B, Löewer M, Diken M, Türeci Ö, et al. A liposomal RNA vaccine inducing neoantigen-specific CD4 + T cells augments the antitumor activity of local radiotherapy in mice. Oncoimmunology. 2020;9(1):1771925. doi:10.1080/2162402X.2020.1771925.
   PubMed Web of Science ®Google Scholar
• Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017;17(3):1326–1335. doi:10.1021/acs.nanolett.6b03329.
   PubMed Web of Science ®Google Scholar
• Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401. doi:10.1038/nature18300.
   PubMed Web of Science ®Google Scholar
• Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW, DeRosa F, Mir FF, Fenton OS, Anderson DG. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 2015;15(11):7300–7306. doi:10.1021/acs.nanolett.5b02497.
   PubMed Web of Science ®Google Scholar
• Lou B, De Koker S, Lau C, Hennink WE, Mastrobattista E. mRNA polyplexes with post-conjugated GALA peptides efficiently target, transfect, and activate antigen presenting cells. Bioconjug Chem. 2019;30(2):461–475. doi:10.1021/acs.bioconjchem.8b00524.
   PubMed Web of Science ®Google Scholar
• Coolen AL, Lacroix C, Mercier-Gouy P, Delaune E, Monge C, Exposito J-Y, Verrier B. Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. Biomaterials. 2019;195:23–37. doi:10.1016/j.biomaterials.2018.12.019.
   PubMed Web of Science ®Google Scholar
• Perche F, Clemencon R, Schulze K, Ebensen T, Guzman CA, Pichon C. Neutral lipopolyplexes for in vivo delivery of conventional and replicative RNA vaccine. Mol Ther Nucleic Acids. 2019;17:767–775. doi:10.1016/j.omtn.2019.07.014.
   PubMedGoogle Scholar
• Walsh EE, Frenck RJ, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–593. doi:10.1038/s41586-020-2639-4.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ. An mRNA vaccine against SARS-CoV-2 — Preliminary report. N Engl J Med. 2020;383(20):1920–1931. doi:10.1056/NEJMoa2022483.
   PubMed Web of Science ®Google Scholar
• Baden LR, El SH, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, Hussein K, Fahoum L, Baruch M, Peer A. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(10):1507–1513. doi:10.1001/jamaoncol.2021.2675.
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626–636. doi:10.1038/s41577-021-00592-1.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD, et al. Bnt162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423. doi:10.1056/NEJMoa2101765.
   PubMed Web of Science ®Google Scholar
• Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829. doi:10.1016/S0140-6736(21)00947-8.
   PubMed Web of Science ®Google Scholar
• Flacco ME, Soldato G, Acuti MC, Carota R, Di Luzio R, Caponetti A, Manzoli L. Interim estimates of COVID-19 vaccine effectiveness in a mass vaccination setting: data from an Italian province. Vaccines (Basel). 2021;9(6). doi:10.3390/vaccines9060628.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, Frankland TB, Ogun OA, Zamparo JM, Gray S. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–1416. doi:10.1016/S0140-6736(21)02183-8.
   PubMed Web of Science ®Google Scholar
• Lopez BJ, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–594. doi:10.1056/NEJMoa2108891.
   PubMed Web of Science ®Google Scholar
• Rovida F, Cassaniti I, Paolucci S, Percivalle E, Sarasini A, Piralla A, Giardina F, Sammartino JC, Ferrari A, Bergami F. SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. Nat Commun. 2021;12(1):6032. doi:10.1038/s41467-021-26154-6.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475–484. doi:10.1038/s41577-021-00578-z.
   PubMed Web of Science ®Google Scholar
• Weinberger B. Vaccines and vaccination against SARS-CoV-2: considerations for the older population. Vaccines (Basel). 2021;9(12). doi:10.3390/vaccines9121435.
   PubMed Web of Science ®Google Scholar
• Nordstrom P, Ballin M, Nordstrom A. Association between risk of COVID-19 infection in nonimmune individuals and COVID-19 immunity in their family members. JAMA Intern Med. 2021;181(12):1589–1595. doi:10.1001/jamainternmed.2021.5814.
   PubMed Web of Science ®Google Scholar
• Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermúdez-González MC, Bielak DA, Carreño JM, Chernet RL, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384(14):1372–1374. doi:10.1056/NEJMc2101667.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):6529. doi:10.1126/science.abf4063.
   Web of Science ®Google Scholar
• Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, Frias EC, Stewart JL, Van Eyk JE, Braun JG. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27(6):981–984. doi:10.1038/s41591-021-01325-6.
   PubMed Web of Science ®Google Scholar
• Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T, Noursadeghi M, Boyton RJ, Semper A, Moon JC, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397(10279):1057–1058. doi:10.1016/S0140-6736(21)00501-8.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501. doi:10.1016/j.cell.2020.05.015.
   PubMed Web of Science ®Google Scholar
• Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325(17):1784–1786. doi:10.1001/jama.2021.4385.
   PubMed Web of Science ®Google Scholar
• Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204–2206. doi:10.1001/jama.2021.7489.
   PubMed Web of Science ®Google Scholar
• Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, Segev DL. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med. 2021;174(9):1330–1332. doi:10.7326/L21-0282.
   PubMed Web of Science ®Google Scholar
• Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, Jabbour R, Hofbauer TM, Merrelaar A, Eder M, Regele F, Doberer K, Spechtl P. Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial. JAMA Intern Med. 2022;182(2):165–171. doi:10.1001/jamainternmed.2021.7372.
   PubMed Web of Science ®Google Scholar
• Karaba AH, Zhu X, Liang T, Wang KH, Rittenhouse A, Akinde O, Eby Y, Ruff JE, Blankson J, Abedon AT. A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. Am J Transplant. 2022;22(4):1253–1260. doi:10.1111/ajt.16933.
   PubMed Web of Science ®Google Scholar
• Peled Y, Ram E, Lavee J, Segev A, Matezki S, Wieder-Finesod A, Halperin R, Mandelboim M, Indenbaum V, Levy I. Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience. J Heart Lung Transplant. 2022;41(2):148–157. doi:10.1016/j.healun.2021.08.010.
   PubMed Web of Science ®Google Scholar
• Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen K-J, Stitz L. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza a virus infection. Nat Biotechnol. 2012;30(12):1210–1216. doi:10.1038/nbt.2436.
   PubMed Web of Science ®Google Scholar
• Fernandez E, Diamond MS. Vaccination strategies against zika virus. Curr Opin Virol. 2017;23:59–67. doi:10.1016/j.coviro.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022;40(6):840–854. doi:10.1038/s41587-022-01294-2.
   PubMed Web of Science ®Google Scholar
• Kauffman KJ, Mir FF, Jhunjhunwala S, Kaczmarek JC, Hurtado JE, Yang JH, Webber MJ, Kowalski PS, Heartlein MW, DeRosa F. Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo. Biomaterials. 2016;109:78–87. doi:10.1016/j.biomaterials.2016.09.006.
   PubMed Web of Science ®Google Scholar
• Thess A, Grund S, Mui BL, Hope MJ, Baumhof P, Fotin-Mleczek M, Schlake T. Sequence-Engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther. 2015;23(9):1456–1464. doi:10.1038/mt.2015.103.
   PubMed Web of Science ®Google Scholar
• Kremsner PG, Ahuad GR, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ. Efficacy and safety of the CVnCov SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2022;22(3):329–340. doi:10.1016/S1473-3099(21)00677-0.
   PubMed Web of Science ®Google Scholar
• Begines B, Ortiz T, Perez-Aranda M, Martínez G, Merinero M, Argüelles-Arias F, Alcudia A. Polymeric nanoparticles for drug delivery: recent developments and future prospects. Nanomaterials (Basel). 2020;10(7):1403. doi:10.3390/nano10071403.
   PubMedGoogle Scholar
• Ibba ML, Ciccone G, Esposito CL, Catuogno S, Giangrande PH. Advances in mRNA non-viral delivery approaches. Adv Drug Deliv Rev. 2021;177:113930. doi:10.1016/j.addr.2021.113930.
   PubMed Web of Science ®Google Scholar
• Zhang NN, Li XF, Deng YQ, Zhao H, Huang Y-J, Yang G, Huang W-J, Gao P, Zhou C, Zhang R-R. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271–1283. doi:10.1016/j.cell.2020.07.024.
   PubMed Web of Science ®Google Scholar
• Muramatsu H, Lam K, Bajusz C, Laczkó D, Karikó K, Schreiner P, Martin A, Lutwyche P, Heyes J, Pardi N. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol Ther. 2022;30(5):1941–1951. doi:10.1016/j.ymthe.2022.02.001.
   PubMed Web of Science ®Google Scholar
• Loomis KH, Lindsay KE, Zurla C, Bhosle SM, Vanover DA, Blanchard EL, Kirschman JL, Bellamkonda RV, Santangelo PJ. In vitro transcribed mRNA vaccines with programmable stimulation of innate immunity. Bioconjug Chem. 2018;29(9):3072–3083. doi:10.1021/acs.bioconjchem.8b00443.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang Y, Miao L, Liu Q, Musetti S, Li J, Huang L. Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer. Mol Ther. 2018;26(1):45–55. doi:10.1016/j.ymthe.2017.10.020.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang L, Xu Z, Miao L, Huang L. mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma. Mol Ther. 2018;26(2):420–434. doi:10.1016/j.ymthe.2017.11.009.
   PubMed Web of Science ®Google Scholar
• Bialkowski L, Van der Jeught K, Bevers S, Tjok JP, Renmans D, Heirman C, Aerts JL, Thielemans K. Immune checkpoint blockade combined with IL-6 and TGF-beta inhibition improves the therapeutic outcome of mRNA-based immunotherapy. Int J Cancer. 2018;143(3):686–698. doi:10.1002/ijc.31331
   PubMed Web of Science ®Google Scholar